Dr. Reddy's Laboratories Limited (RDY)
USD 14.55
(0.48%)
USD 14.55
(0.48%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 67.72 Billion INR | -29.66% |
| 2023 | 96.28 Billion INR | 135.88% |
| 2022 | 40.81 Billion INR | 13.19% |
| 2021 | 36.06 Billion INR | -2.68% |
| 2020 | 37.05 Billion INR | 77.4% |
| 2019 | 20.88 Billion INR | 75.28% |
| 2018 | 11.91 Billion INR | -11.71% |
| 2017 | 13.49 Billion INR | -54.43% |
| 2016 | 29.61 Billion INR | 12.68% |
| 2015 | 26.28 Billion INR | 0.98% |
| 2014 | 26.03 Billion INR | 23.3% |
| 2013 | 21.11 Billion INR | 15.67% |
| 2012 | 18.25 Billion INR | 44.54% |
| 2011 | 12.62 Billion INR | 528.88% |
| 2010 | 2 Billion INR | 170.85% |
| 2009 | -2.83 Billion INR | -184.4% |
| 2008 | 3.35 Billion INR | -70.16% |
| 2007 | 11.25 Billion INR | 678.25% |
| 2006 | 1.44 Billion INR | 494.5% |
| 2005 | -366.46 Million INR | -117.58% |
| 2004 | 2.08 Billion INR | -37.52% |
| 2003 | 3.33 Billion INR | -34.06% |
| 2002 | 5.06 Billion INR | 240.61% |
| 2001 | 1.48 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | 14.78 Billion INR | -14.37% |
| 2024 Q3 | 17.26 Billion INR | -3.36% |
| 2024 Q1 | 17.63 Billion INR | -19.66% |
| 2024 Q2 | 17.86 Billion INR | 1.31% |
| 2024 FY | 67.72 Billion INR | -29.66% |
| 2023 Q3 | 16.42 Billion INR | 1.85% |
| 2023 Q4 | 21.95 Billion INR | 33.65% |
| 2023 FY | 96.28 Billion INR | 135.88% |
| 2023 Q2 | 16.12 Billion INR | 32.06% |
| 2023 Q1 | 12.21 Billion INR | 66.01% |
| 2022 Q3 | 9.23 Billion INR | -23.77% |
| 2022 Q4 | 7.35 Billion INR | -20.35% |
| 2022 Q2 | 12.11 Billion INR | 83.37% |
| 2022 Q1 | 6.6 Billion INR | -12.77% |
| 2022 FY | 40.81 Billion INR | 13.19% |
| 2021 Q1 | 8.1 Billion INR | 22.8% |
| 2021 FY | 36.06 Billion INR | -2.68% |
| 2021 Q2 | 8.31 Billion INR | 2.52% |
| 2021 Q3 | 2.19 Billion INR | -73.54% |
| 2021 Q4 | 7.57 Billion INR | 244.43% |
| 2020 Q1 | 7.94 Billion INR | 48.62% |
| 2020 FY | 37.05 Billion INR | 77.4% |
| 2020 Q4 | 6.6 Billion INR | 212.49% |
| 2020 Q3 | -5.86 Billion INR | -180.22% |
| 2020 Q2 | 7.31 Billion INR | -7.91% |
| 2019 Q2 | 5.04 Billion INR | 5.83% |
| 2019 Q1 | 4.76 Billion INR | 80.13% |
| 2019 FY | 20.88 Billion INR | 75.28% |
| 2019 Q3 | 5.72 Billion INR | 13.54% |
| 2019 Q4 | 5.34 Billion INR | -6.7% |
| 2018 Q2 | 3.8 Billion INR | 740.62% |
| 2018 FY | 11.91 Billion INR | -11.71% |
| 2018 Q4 | 2.64 Billion INR | -47.16% |
| 2018 Q3 | 5 Billion INR | 31.54% |
| 2018 Q1 | 453 Million INR | -85.55% |
| 2017 FY | 13.49 Billion INR | -54.43% |
| 2017 Q3 | 5.78 Billion INR | 70.97% |
| 2017 Q2 | 3.38 Billion INR | 185.02% |
| 2017 Q1 | 1.18 Billion INR | -76.58% |
| 2017 Q4 | 3.13 Billion INR | -45.85% |
| 2016 Q2 | 9.25 Billion INR | 20.03% |
| 2016 Q3 | 7.57 Billion INR | -18.14% |
| 2016 FY | 29.61 Billion INR | 12.68% |
| 2016 Q1 | 7.71 Billion INR | 26.01% |
| 2016 Q4 | 5.07 Billion INR | -33.07% |
| 2015 FY | 26.28 Billion INR | 0.98% |
| 2015 Q2 | 6.46 Billion INR | -0.15% |
| 2015 Q1 | 6.47 Billion INR | 10.55% |
| 2015 Q4 | 6.12 Billion INR | -15.31% |
| 2015 Q3 | 7.22 Billion INR | 11.77% |
| 2014 FY | 26.03 Billion INR | 23.3% |
| 2014 Q4 | 5.85 Billion INR | -32.24% |
| 2014 Q3 | 8.64 Billion INR | 17.45% |
| 2014 Q2 | 7.36 Billion INR | 76.46% |
| 2014 Q1 | 4.17 Billion INR | -43.84% |
| 2013 Q4 | 7.42 Billion INR | 57.09% |
| 2013 Q1 | 3.91 Billion INR | -6.07% |
| 2013 Q2 | 5.24 Billion INR | 33.79% |
| 2013 FY | 21.11 Billion INR | 15.67% |
| 2013 Q3 | 4.72 Billion INR | -9.81% |
| 2012 Q1 | 2.78 Billion INR | -27.43% |
| 2012 Q3 | 7.54 Billion INR | 101.52% |
| 2012 FY | 18.25 Billion INR | 44.54% |
| 2012 Q4 | 4.17 Billion INR | -44.73% |
| 2012 Q2 | 3.74 Billion INR | 34.28% |
| 2011 Q2 | 3.22 Billion INR | 22.93% |
| 2011 FY | 12.62 Billion INR | 528.88% |
| 2011 Q4 | 3.84 Billion INR | 31.03% |
| 2011 Q3 | 2.93 Billion INR | -9.11% |
| 2011 Q1 | 2.62 Billion INR | 24.35% |
| 2010 Q1 | 3.29 Billion INR | 134.8% |
| 2010 Q2 | 2.54 Billion INR | -22.79% |
| 2010 Q3 | -5.94 Billion INR | -333.73% |
| 2010 Q4 | 2.11 Billion INR | 135.5% |
| 2010 FY | 2 Billion INR | 170.85% |
| 2009 Q3 | 3.75 Billion INR | 112.57% |
| 2009 FY | -2.83 Billion INR | -184.4% |
| 2009 Q4 | -9.46 Billion INR | -352.3% |
| 2009 Q2 | 1.76 Billion INR | 10.48% |
| 2009 Q1 | 1.59 Billion INR | 27.35% |
| 2008 Q3 | -1.27 Billion INR | -175.6% |
| 2008 FY | 3.35 Billion INR | -70.16% |
| 2008 Q1 | 2.06 Billion INR | -39.78% |
| 2008 Q2 | 1.68 Billion INR | -18.66% |
| 2008 Q4 | 1.25 Billion INR | 198.62% |
| 2007 Q1 | 1.82 Billion INR | 811.28% |
| 2007 Q3 | 2.11 Billion INR | -45.33% |
| 2007 Q2 | 3.86 Billion INR | 112.06% |
| 2007 FY | 11.25 Billion INR | 678.25% |
| 2007 Q4 | 3.43 Billion INR | 62.77% |
| 2006 Q2 | 692.18 Million INR | 136.84% |
| 2006 Q1 | 292.26 Million INR | 138.68% |
| 2006 FY | 1.44 Billion INR | 494.5% |
| 2006 Q4 | -255.92 Million INR | -134.25% |
| 2006 Q3 | 747.17 Million INR | 7.94% |
| 2005 Q1 | 43.81 Million INR | 114.86% |
| 2005 Q4 | -755.59 Million INR | -746.09% |
| 2005 Q3 | -89.3 Million INR | -118.79% |
| 2005 FY | -366.46 Million INR | -117.58% |
| 2005 Q2 | 475.22 Million INR | 984.6% |
| 2004 Q1 | 846.04 Million INR | 53.25% |
| 2004 FY | 2.08 Billion INR | -37.52% |
| 2004 Q3 | 575.06 Million INR | -40.39% |
| 2004 Q4 | -294.95 Million INR | -151.29% |
| 2004 Q2 | 964.71 Million INR | 14.03% |
| 2003 Q2 | 926.37 Million INR | -24.88% |
| 2003 FY | 3.33 Billion INR | -34.06% |
| 2003 Q1 | 1.23 Billion INR | 47.28% |
| 2003 Q3 | 629.11 Million INR | -32.09% |
| 2003 Q4 | 552.08 Million INR | -12.24% |
| 2002 Q1 | 516.68 Million INR | 0.0% |
| 2002 Q2 | 2.22 Billion INR | 329.98% |
| 2002 FY | 5.06 Billion INR | 240.61% |
| 2002 Q4 | 837.26 Million INR | -43.66% |
| 2002 Q3 | 1.48 Billion INR | -33.11% |
| 2001 FY | 1.48 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 204.37 Million USD | -33039.734% |
| Bausch Health Companies Inc. | 963 Million USD | -6933.126% |
| Catalent, Inc. | -749 Million USD | 9142.59% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 9423.926% |
| Elanco Animal Health Incorporated | 326 Million USD | -20675.767% |
| Perrigo Company plc | 151.9 Million USD | -44487.887% |
| Teva Pharmaceutical Industries Limited | 433 Million USD | -15541.801% |
| Zoetis Inc. | 3.06 Billion USD | -2106.875% |